NSP vs. NBIX
Compare and contrast key facts about Insperity, Inc. (NSP) and Neurocrine Biosciences, Inc. (NBIX).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: NSP or NBIX.
Correlation
The correlation between NSP and NBIX is 0.47, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.
Performance
NSP vs. NBIX - Performance Comparison
Loading data...
Key characteristics
NSP:
-0.87
NBIX:
-0.41
NSP:
-1.24
NBIX:
-0.36
NSP:
0.85
NBIX:
0.94
NSP:
-0.74
NBIX:
-0.45
NSP:
-1.92
NBIX:
-1.01
NSP:
18.64%
NBIX:
19.05%
NSP:
40.92%
NBIX:
41.57%
NSP:
-95.37%
NBIX:
-97.21%
NSP:
-47.70%
NBIX:
-24.52%
Fundamentals
NSP:
$2.50B
NBIX:
$11.63B
NSP:
$1.69
NBIX:
$2.95
NSP:
39.01
NBIX:
39.22
NSP:
1.42
NBIX:
0.27
NSP:
0.38
NBIX:
4.82
NSP:
20.98
NBIX:
4.59
NSP:
$6.64B
NBIX:
$2.41B
NSP:
$1.02B
NBIX:
$2.37B
NSP:
$158.00M
NBIX:
$539.80M
Returns By Period
In the year-to-date period, NSP achieves a -14.37% return, which is significantly higher than NBIX's -15.23% return. Over the past 10 years, NSP has outperformed NBIX with an annualized return of 11.95%, while NBIX has yielded a comparatively lower 10.61% annualized return.
NSP
-14.37%
-20.49%
-16.11%
-35.60%
7.55%
11.95%
NBIX
-15.23%
27.55%
-7.98%
-15.35%
0.38%
10.61%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
NSP vs. NBIX — Risk-Adjusted Performance Rank
NSP
NBIX
NSP vs. NBIX - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Insperity, Inc. (NSP) and Neurocrine Biosciences, Inc. (NBIX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Loading data...
Dividends
NSP vs. NBIX - Dividend Comparison
NSP's dividend yield for the trailing twelve months is around 3.64%, while NBIX has not paid dividends to shareholders.
| TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
NSP Insperity, Inc. | 3.64% | 3.06% | 1.90% | 1.77% | 3.18% | 1.97% | 1.39% | 0.86% | 2.75% | 1.37% | 1.77% | 8.08% |
NBIX Neurocrine Biosciences, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Drawdowns
NSP vs. NBIX - Drawdown Comparison
The maximum NSP drawdown since its inception was -95.37%, roughly equal to the maximum NBIX drawdown of -97.21%. Use the drawdown chart below to compare losses from any high point for NSP and NBIX. For additional features, visit the drawdowns tool.
Loading data...
Volatility
NSP vs. NBIX - Volatility Comparison
Insperity, Inc. (NSP) has a higher volatility of 17.72% compared to Neurocrine Biosciences, Inc. (NBIX) at 12.48%. This indicates that NSP's price experiences larger fluctuations and is considered to be riskier than NBIX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading data...
Financials
NSP vs. NBIX - Financials Comparison
This section allows you to compare key financial metrics between Insperity, Inc. and Neurocrine Biosciences, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
NSP vs. NBIX - Profitability Comparison
NSP - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Insperity, Inc. reported a gross profit of 310.00M and revenue of 1.86B. Therefore, the gross margin over that period was 16.6%.
NBIX - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Neurocrine Biosciences, Inc. reported a gross profit of 563.40M and revenue of 572.60M. Therefore, the gross margin over that period was 98.4%.
NSP - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Insperity, Inc. reported an operating income of 68.00M and revenue of 1.86B, resulting in an operating margin of 3.7%.
NBIX - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Neurocrine Biosciences, Inc. reported an operating income of 23.60M and revenue of 572.60M, resulting in an operating margin of 4.1%.
NSP - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Insperity, Inc. reported a net income of 51.00M and revenue of 1.86B, resulting in a net margin of 2.7%.
NBIX - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Neurocrine Biosciences, Inc. reported a net income of 7.90M and revenue of 572.60M, resulting in a net margin of 1.4%.